Skip to content
10-Q

Quarterly Report

Astria Therapeutics, Inc.

0001410578-25-001224

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 56.43M sh
Shares Diluted Q1 2025 · Mar 31, 2025 58.01M sh
Shares Diluted Q1 2025 · Mar 31, 2024 52.29M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$34.02M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$19.09M
Short Term Investments Q1 2025 · Mar 31, 2025 $240.68M
Short Term Investments Q1 2025 · Dec 31, 2024 $268.31M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $54.39M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $59.82M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $172.01M
Stockholders Equity Q1 2025 · Mar 31, 2025 $289.29M
Stockholders Equity Q1 2025 · Dec 31, 2024 $319.26M
Stockholders Equity Q1 2025 · Mar 31, 2024 $367.74M
Stockholders Equity Q1 2025 · Dec 31, 2023 $243.12M
Current Liabilities Q1 2025 · Mar 31, 2025 $17.43M
Current Liabilities Q1 2025 · Dec 31, 2024 $19.13M
Total Liabilities Q1 2025 · Mar 31, 2025 $21.1M
Total Liabilities Q1 2025 · Dec 31, 2024 $23.1M
Current Assets Q1 2025 · Mar 31, 2025 $302.97M
Current Assets Q1 2025 · Dec 31, 2024 $334.64M
Total Assets Q1 2025 · Mar 31, 2025 $310.39M
Total Assets Q1 2025 · Dec 31, 2024 $342.36M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.58
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.38
Eps Basic Q1 2025 · Mar 31, 2025 −$0.58
Eps Basic Q1 2025 · Mar 31, 2024 −$0.38
Sga Expense Q1 2025 · Mar 31, 2025 $9.21M
Sga Expense Q1 2025 · Mar 31, 2024 $8.42M
Net Income Q1 2025 · Mar 31, 2025 −$33.71M
Net Income Q1 2025 · Mar 31, 2024 −$19.93M
Operating Income Q1 2025 · Mar 31, 2025 −$37M
Operating Income Q1 2025 · Mar 31, 2024 −$24.15M